5.1 Infectious Disease
Key Takeaways
- Empiric therapy targets the most likely pathogens at a site of infection while cultures are pending; targeted (definitive) therapy narrows coverage once susceptibilities return.
- Outpatient community-acquired pneumonia in an otherwise healthy adult is treated with a macrolide, doxycycline, or amoxicillin; comorbidities or risk factors push toward respiratory fluoroquinolone or beta-lactam plus macrolide combinations.
- Uncomplicated cystitis first-line options include nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin; nitrofurantoin is avoided when creatinine clearance is markedly reduced because urinary concentrations fall.
- Antimicrobial stewardship core actions include de-escalation, IV-to-oral conversion, dose optimization by pharmacokinetic-pharmacodynamic targets, and defined durations to limit resistance and Clostridioides difficile.
- Adult immunization sequencing concepts (live vs inactivated spacing, pneumococcal conjugate-then-polysaccharide logic, and dose intervals) are high-yield clinical-judgment content.
Why Infectious Disease Is High-Yield
The Person-Centered Assessment and Treatment Planning domain is 40% of the NAPLEX, and infectious disease (ID) appears repeatedly because every antimicrobial decision blends microbiology, pharmacokinetics, patient factors, and public-health stewardship. The exam rarely asks you to recall a drug in isolation; it gives a patient scenario and asks for the best therapeutic choice, an adjustment for renal function, or a stewardship action.
Think of every ID question as four linked decisions: (1) what is the likely pathogen at this site, (2) what drug covers it with acceptable safety, (3) what dose and route fit this patient, and (4) when should therapy be narrowed or stopped.
Antimicrobial Spectrum and Selection
Spectrum of activity describes which organisms a drug reliably covers. A useful mental model groups agents by their dependable coverage:
| Coverage need | Representative agents | Common clinical use |
|---|---|---|
| Gram-positive (incl. MSSA) | Cefazolin, nafcillin/oxacillin, amoxicillin | Skin/soft-tissue, surgical prophylaxis |
| MRSA (methicillin-resistant S. aureus) | Vancomycin, linezolid, daptomycin (not for pneumonia) | Purulent SSTI, MRSA bacteremia |
| Gram-negative incl. Pseudomonas | Piperacillin-tazobactam, cefepime, meropenem | Hospital-acquired/sepsis with Pseudomonas risk |
| Atypicals (Mycoplasma, Chlamydophila, Legionella) | Azithromycin, doxycycline, levofloxacin | Community pneumonia atypical coverage |
| Anaerobes | Metronidazole, piperacillin-tazobactam, carbapenems | Intra-abdominal, aspiration |
Empiric therapy is started before culture results based on the most probable pathogens for the syndrome and the patient's exposures (recent hospitalization, prior resistant organisms, severity). Targeted (definitive) therapy narrows the regimen once the organism and susceptibilities are known. On the exam, the correct answer after a susceptibility report is almost always the narrowest effective agent, not continuation of broad coverage.
Common Infection Syndromes
Community-Acquired Pneumonia (CAP)
For a previously healthy outpatient with no recent antibiotics, reasonable empiric options include a macrolide (azithromycin), doxycycline, or amoxicillin. With comorbidities (chronic heart, lung, liver, or kidney disease; diabetes; recent antibiotics), guidelines support a respiratory fluoroquinolone (levofloxacin or moxifloxacin) or a beta-lactam plus a macrolide. Inpatient and severe CAP escalate further and add coverage based on local resistance and risk factors for MRSA or Pseudomonas.
Urinary Tract Infection (UTI)
Uncomplicated cystitis first-line agents are nitrofurantoin, trimethoprim-sulfamethoxazole (where local resistance is acceptable), and fosfomycin. Nitrofurantoin should be avoided when creatinine clearance is substantially reduced because it fails to reach therapeutic urinary concentrations and toxicity risk rises; it also does not treat pyelonephritis because it lacks tissue penetration. Pyelonephritis requires an agent achieving renal-tissue levels (a fluoroquinolone or an appropriate beta-lactam, guided by susceptibilities).
Skin and Soft-Tissue Infection (SSTI)
Non-purulent cellulitis is usually streptococcal/MSSA and treated with a beta-lactam (e.g., cephalexin). Purulent infection (abscess) raises MRSA probability; incision and drainage is central, with MRSA-active oral therapy (trimethoprim-sulfamethoxazole or doxycycline) when antibiotics are indicated.
Sepsis
In suspected sepsis/septic shock, the high-yield concepts are obtaining cultures before antibiotics when feasible, administering broad-spectrum empiric therapy promptly (early appropriate coverage improves outcomes), supporting perfusion, and then de-escalating once the organism is identified. The exam tests the principle of early appropriate broad coverage followed by narrowing, not a memorized minute-by-minute protocol.
Antimicrobial Stewardship
Antimicrobial stewardship is the coordinated effort to optimize antimicrobial use to improve outcomes while minimizing resistance, toxicity, cost, and Clostridioides difficile infection. Pharmacists drive several core interventions:
- De-escalation: narrow from empiric broad therapy to a targeted agent once cultures return.
- IV-to-oral conversion: switch to oral therapy when the patient is clinically improving, tolerating oral intake, and the oral agent has adequate bioavailability (e.g., fluoroquinolones, linezolid, metronidazole, fluconazole).
- Dose optimization: apply pharmacokinetic-pharmacodynamic targets — time-dependent killers (beta-lactams) benefit from more frequent or extended infusions, while concentration-dependent killers (aminoglycosides, fluoroquinolones) rely on a high peak relative to the MIC.
- Duration limits: use the shortest effective course; many common infections are now treated for shorter, evidence-based durations.
- Allergy clarification: distinguish a true IgE-mediated penicillin allergy from intolerance so patients are not unnecessarily denied first-line beta-lactams.
Stewardship test cue: If a vignette shows a clinically improving patient on broad IV therapy with susceptibilities back, the best answer is usually de-escalate and/or convert to oral — not continue current therapy.
Adult Immunization Sequencing Concepts
The exam emphasizes immunization logic rather than rote schedules. Durable principles:
| Concept | Principle |
|---|---|
| Live vaccine spacing | Two different live vaccines not given the same day should generally be separated by about 4 weeks; live vaccines are generally avoided in pregnancy and significant immunosuppression. |
| Inactivated vaccines | Can generally be co-administered with other vaccines and have no required spacing from live vaccines. |
| Pneumococcal logic | When both a conjugate and a polysaccharide product are indicated in series, the conjugate is given first, followed by the polysaccharide after the recommended interval. |
| Tetanus-containing | A wound-management decision depends on wound type and prior tetanus doses/timing. |
| High-dose intervals | Multi-dose series (e.g., hepatitis B, shingles) require minimum intervals; doses given too early may not count. |
Reason from the patient's age, immune status, pregnancy status, and prior dose history rather than memorizing a calendar.
Putting It Together
A strong ID answer respects the site (does the drug penetrate there?), the bug (is it in the spectrum?), the patient (renal/hepatic function, allergy, pregnancy), and stewardship (narrowest effective option for the shortest effective time).
A previously healthy 34-year-old woman presents with 2 days of dysuria and urinary frequency, no fever, no flank pain, and is not pregnant. Urinalysis suggests uncomplicated cystitis and her renal function is normal. Which empiric choice is most appropriate first-line therapy?
A patient with hospital-acquired pneumonia is started on empiric piperacillin-tazobactam plus vancomycin. On day 3 the patient is clinically improving, afebrile, and tolerating oral intake; cultures grow methicillin-susceptible Staphylococcus aureus (MSSA) susceptible to a narrow beta-lactam. Which action best reflects antimicrobial stewardship?
A 28-year-old previously healthy outpatient with no recent antibiotic use and no comorbidities is diagnosed with mild community-acquired pneumonia (CAP) and can be managed at home. Which empiric regimen is a reasonable first-line option?